Porton Pharma Solutions projects Q3 2025 return to profit

Porton Pharma Solutions projects a return to profitability for the first three quarters of 2025, anticipating a net profit attributable to shareholders of CNY 732 million to CNY 882 million. This marks a substantial improvement from the net loss of CNY 206.43 million reported in the same period of 2024. Excluding non-recurring gains and losses, the company expects a net profit of CNY 500 million to CNY 650 million, compared to a loss of CNY 213.5 million previously.

The positive outlook is driven by an estimated 17% to 21% year-on-year increase in operating revenue, reaching CNY 2.48 billion to CNY 2.58 billion. This growth is attributed to the expansion of client and product pipelines, enhanced R&D capabilities, and improved product delivery, contributing to stable growth across both domestic and international markets.

The company's improved financial performance also reflects benefits from increased operational scale, ongoing cost reduction and efficiency initiatives, and a sustained improvement in overall gross profit margin.